Five Prime Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2018-10-18: Study NCT04074759; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2018-09-14: Study NCT03694522; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2018-03-27: Study NCT03514121; Company role Lead sponsor; Phase Early Phase 1; Status Terminated.
- 2017-11-30: Study NCT03343301; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2018-10-18 | NCT04074759 FPT155 in Patients With Advanced Solid Tumors | Lead sponsor | Phase 1 | Terminated Results posted | Advanced Solid Tumors | 80 | 2021-08-10 |
| 2018-09-14 | NCT03694522 A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer | Lead sponsor | Phase 2 | Completed Results posted | Gastric Cancer | 155 | 2022-05-13 |
| 2018-03-27 | NCT03514121 FPA150 in Patients With Advanced Solid Tumors | Lead sponsor | Early Phase 1 | Terminated Results posted | Breast Cancer; Ovarian Cancer; Endometrial Cancer; Advanced Solid Tumors | 95 | 2021-04-21 |
| 2017-11-30 | NCT03343301 A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer | Lead sponsor | Phase 1 | Completed Results posted | Gastrointestinal Cancer; Gastrointestinal Cancer Metastatic; Gastric Cancer | 12 | 2019-01-31 |
| 2015-09-08 | NCT02526017 Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers | Lead sponsor | Phase 1 | Completed Results posted | Advanced Solid Tumors; Head and Neck Cancer; Pancreatic Cancer; Ovarian Cancer; Renal Cell Carcinoma; Malignant Glioma; Non-small Cell Lung Cancer | 313 | 2019-11-18 |
| 2015-06 | NCT02471716 Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Pigmented Villonodular Synovitis; Tenosynovial Giant Cell Tumor | 66 | 2020-04-30 |
| 2014-11 | NCT02318329 Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors | Lead sponsor | Phase 1 | Completed Results posted | Advanced Solid Tumors; Gastric Cancer; Transitional Cell Carcinoma of the Bladder | 79 | 2019-06-30 |
| 2013-10 | NCT01962337 Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects | Lead sponsor | Phase 1 | Terminated | Healthy; Rheumatoid Arthritis | 66 | 2016-04 |
| 2011-01 | NCT01244438 Study of FP-1039 in Subjects With Endometrial Cancers | Lead sponsor | Phase 2 | Withdrawn | Endometrial Cancers With FGFR2 Mutations | 0 | 2012-12 |
| 2008-07 | NCT00687505 Safety Study of FP-1039 To Treat Cancer | Lead sponsor | Phase 1 | Completed | Advanced Cancer | 39 | 2011-06 |
| NCT03801278 An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer | Lead sponsor | Expanded_access | No longer available | Recurrent Bladder Cancer |